Table 2.

Patient-Reported Outcomes^a

Variable	Baseline	Mean AUC		AUC Differenceb
		Discontinued Statin (n = 189)	Continued Statin (n = 192)	Estimated (95% CI)	P Value
Quality of life
Overall	6.12	6.53	6.35	0.18 (−0.28 to 0.64)	.44
Physical	5.19	5.43	5.51	−0.08 (−0.43 to 0.26)	.64
Psychological	7.21	7.38	6.99	0.39 (−0.02 to 0.80)	.06
Well-being	7.30	7.37	7.05	0.32 (0.00 to 0.64)	.05
Support	8.31	8.38	7.86	0.53 (0.16 to 0.90)	.005
Total	6.98	7.11	6.85	0.26 (0.02 to 0.50)	.04
Symptoms
Standard	27.2	25.2	27.4	−2.2 (−5.0 to 0.6)	.13
Statin items	7.1	7.0	7.2	−0.2 (−1.4 to 0.9)	.71
All items	34.6	32.4	34.8	−2.5 (−6.0 to 1.1)	.18
AKPS score	54.3	47.7	48.5	−0.8 (−4.1 to 2.5)	.63
Nonstatin medications
Total	10.9	10.1	10.8	−0.7 (−1.3 to −0.1)	.03
Regular	8.9	8.4	8.7	−0.3 (−0.8 to 0.3)	.34
PRN, days
<½c	0.9	0.9	1.1	−0.2 (−0.5 to 0.1)	.16
≥½d	1.0	0.9	1.0	−0.1 (−0.3 to 0.1)	.33
Satisfaction with care (willing to recommend)	4.55	4.63	4.55	0.08 (−0.05 to 0.20)	.22

Abbreviations: AKPS, Australia-Modified Karnofsky Performance Status; AUC, area under the curve; PRN, administered as needed.

^aPatient-reported outcome results at baseline (week 0), group estimates at week 20, and AUC mean during 20 weeks modeled using all study data.

^bDiscontinued - continued.

^cNumber of PRN nonstatin medications that were administered on more than half of the days during the study.

^dNumber of PRN nonstatin medications that were administered on less than half of the days during the study.